Non-Invasive Skin Fluid Biomarkers in Babies with and without Eczema

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study uses a non-invasive micro-suction device to extract interstitial skin fluid (ISF) from babies to compare chemical signals in healthy skin versus skin affected by eczema. It aims to show the device is tolerable and capable of obtaining biomarker data without causing discomfort or skin damage. Researchers will analyze ISF, skin swabs, and tape strips to compare immune-related markers, microbiome, and metabolome between groups and between lesional and non-lesional skin in eczema cases. The study plans to enroll 30 infants (15 healthy, 15 with eczema) in a single visit of 1–1.5 hours, collecting demographic and clinical information, eczema severity (for affected infants), and ISF samples. Findings could illuminate signals involved in eczema inflammation and inform future prevention and treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Healthy babies and babies with atopic dermatitis up to 6 months old.
2. Ability of parents/guardians/caregivers to provide written informed consent for study participation.
3. Willingness of parents/guardians/caregivers to comply with all study requirements.
4. Parents/guardians/caregivers competent use of English language.

Exclusion Criteria:

1. Parents/guardians/caregivers unable to give informed consent.
2. Preterm birth (defined as birth before 37 completed weeks gestation).
3. Significant inflammatory skin disease at birth.
4. Baby has any other serious health issue.

Where it's running

• St Thomas' Hospital
  London, United Kingdom Recruiting

Study contacts

• Principal investigator: Carsten Flohr — King's College London
• Study coordinator: Preeti Khurana
• Email: gstt.carestudy@nhs.net
• Phone: 020 7188 7188

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Digital mindfulness app for teens with eczema

  Teens with moderate to severe eczema try a digital mindfulness app to see if it helps control symptoms and improve quality of life.

  Recruiting at 2 sites Weill Medical College of Cornell University · New York, New York and 1 other locations · NCT07746427

• Camoteskimab in adults with moderate-to-severe atopic dermatitis

  This trial tests different doses of camoteskimab versus placebo to see if it helps adults with moderate-to-severe atopic dermatitis who have not fully responded to standard treatments.

  Recruiting at 31 sites Phase 2 Apollo Therapeutics Ltd · Birmingham, Alabama and 84 other locations · NCT07599813

• Low-sodium diet and salt tablets to see if eczema improves

  This study tests whether a low-sodium diet can lessen eczema symptoms in adults with atopic dermatitis, using a cross-over design with sodium tablets and placebo to see if salt intake changes skin sodium and severity.

  Recruiting at 2 sites Phase 4 University of California, San Francisco · San Francisco, California and 1 other locations · NCT07447063

• Soquelitinib for adults with moderate to severe atopic dermatitis

  This 12-week test gives adults with moderate to severe atopic dermatitis daily soquelitinib or a placebo to see if their skin and itch improve and to track side effects.

  Recruiting Phase 2 Corvus Pharmaceuticals, Inc. · South San Francisco, California · NCT07441395

• GX-03 topical treatment for adults with moderate to severe eczema

  This study will test whether applying GX-03, a topical emollient, twice daily for 8 weeks reduces eczema severity and itch in adults with moderate to severe atopic dermatitis compared with a petrolatum-based vehicle.

  Recruiting Phase 2/3 Turn Therapeutics · Irving, Texas · NCT07355075

• IMG-007 for adults with moderate-to-severe atopic dermatitis.

  This study will test if different doses of IMG-007 reduce skin inflammation and itching in adults with moderate-to-severe atopic dermatitis compared with a placebo.

  Recruiting at 23 sites Phase 2 Inmagene LLC · Lancaster, California and 29 other locations · NCT07037901

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.